Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2026
Reply to Woodie, et al., “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX.”
Torres T, Blauvelt A, Strober B, van de Kerkhof P, Eakin G, Winthrop K, Gelfand J. Reply to Woodie, et al., “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX.”. Journal Of The American Academy Of Dermatology 2026 PMID: 41850622, DOI: 10.1016/j.jaad.2025.12.129.Peer-Reviewed Original ResearchThe Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, Golant A, Schlesinger T, Strober B, Song E, Stein Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus. SKIN The Journal Of Cutaneous Medicine 2026, 10: s724. DOI: 10.25251/3j4scd05.Peer-Reviewed Original ResearchSystemic corticosteroidsStrength of Recommendation TaxonomyAtopic dermatitisExpert consensusConsensus statementSystemic corticosteroid exposureSystemic therapy trialsLiterature searchManagement of ADChronic inflammatory diseaseAdvanced systemic treatmentsComprehensive literature searchStrength of recommendationsSystemic treatmentTherapy trialsInflammatory diseasesAlternative therapiesEvidence-based thresholdsCorticosteroidsRoutine useRecommendation TaxonomyCombination of keywordsDermatitisEligible articlesAdverse effectsBimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Warren R, Strober B, Jullien D, Lebwohl M, Eyerich K, Langley R, Szilagyi B, Warham R, Armstrong A. Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials. SKIN The Journal Of Cutaneous Medicine 2026, 10: s758. DOI: 10.25251/0bnq3318.Peer-Reviewed Original ResearchOpen-label extensionPercentage of patientsPhase 3 trialSkin clearanceProcedural dataStudy visitsDisease controlTreatment due to lackYear 4Remission of psoriasisComplete skin clearanceBimekizumabAdverse eventsNon-respondersTreatment guidelinesPASIQ8WBE SUREPatientsHigher disease controlLong-term maintenancePsoriasisQ4WRemissionWeeks074 Efficacy of Apremilast in Pediatric Patients With Plaque Psoriasis According to Disease Duration in the SPROUT Randomized Controlled Trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. 074 Efficacy of Apremilast in Pediatric Patients With Plaque Psoriasis According to Disease Duration in the SPROUT Randomized Controlled Trial. Journal Of Investigative Dermatology 2026, 146: s18. DOI: 10.1016/s0022-202x(26)00609-3.Peer-Reviewed Original ResearchStatic Physician's Global AssessmentBody surface areaDisease durationPlaque psoriasisTopical therapyPediatric patientsModerate to severe PsOGlobal assessmentLong-term disease burdenEfficacy of apremilastOral systemic therapyPhysician global assessmentPost Hoc AnalysisPASI-90Randomized Controlled TrialsSystemic therapyPASI-75Psoriasis AreaDisease activityDisease courseAdult studiesPlaceboPediatric ptsHoc AnalysisQuality of lifeApremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial. Journal Of The American Academy Of Dermatology 2026 PMID: 41643746, DOI: 10.1016/j.jaad.2026.01.072.Peer-Reviewed Original ResearchIn Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025)
Strober B. In Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025). Journal Of The American Academy Of Dermatology 2026, 94: e139-e140. DOI: 10.1016/j.jaad.2025.10.060.Peer-Reviewed Original ResearchBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.
Lebwohl M, Krueger J, Koo J, Han G, Armstrong A, Strober B, Kircik L. Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence. Journal Of Drugs In Dermatology 2026, 25: 211-220. PMID: 41779761, DOI: 10.36849/jdd.9739.Peer-Reviewed Original ResearchConceptsReal-world studyPlaque psoriasisClinical trialsRate of complete responseModerate-to-severe psoriasisChronic immune-mediated diseaseSafety of brodalumabLong-term clinical trialsRisk of malignancyAdverse cardiac eventsFatal adverse eventsHuman monoclonal antibodyImmune-mediated diseasesDisease controlComplete responseSystemic therapySkin clearanceTherapeutic optionsCardiac eventsSafety profileSustained disease controlAdverse eventsBrodalumabInterleukin-17Proinflammatory cytokinesThe role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, K. Golant A, Schlesinger T, Strober B, Song E, Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus. Archives Of Dermatological Research 2026, 318: 44. DOI: 10.1007/s00403-025-04502-6.Peer-Reviewed Original ResearchSystemic corticosteroid exposureSystemic corticosteroidsStrength of Recommendation TaxonomyAtopic dermatitisSystemic therapyLong-term disease controlConsensus statementDuration-dependent toxicitySteroid-sparing optionsSystemic therapy trialsAssociated with serious adverse eventsLong-term benefit-risk profileModerate-to-severe ADSerious adverse eventsBenefit-risk profileExpert consensusChronic inflammatory diseaseAdvanced systemic treatmentsComprehensive literature searchFoundational therapySystemic treatmentTherapy trialsAdverse eventsIntramuscular doseGuideline recommendations
2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial
Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, Abe M, Strober B, Gooderham M, Hara Y, Zhang W, Shimauchi J, Yaguchi M, Kimura T, Ogawa R, Amouzadeh H, Murakami M. Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial. Dermatology And Therapy 2025, 16: 709-712. PMID: 41387650, PMCID: PMC12936317, DOI: 10.1007/s13555-025-01583-z.Peer-Reviewed Original ResearchPhase 3 studyPalmoplantar pustulosisWeeks of treatmentPatient-reported qualityJapanese patientsTreatment optionsTopical treatmentSide effectsResponse to topical treatmentPatient-reported quality of lifeSafety of apremilastOral treatment optionsPhase 3 trialSoft stoolClinical severityApremilastPlaceboPatientsQuality of lifePustulosisWeeksTreatmentConsistent with previous studiesOptionsNasopharyngitisLaboratory monitoring in patients with moderate to severe plaque psoriasis
Fenkel J, Osborne J, Armstrong A, Strober B, Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis. Journal Of Dermatological Treatment 2025, 36: 2583227. PMID: 41346021, DOI: 10.1080/09546634.2025.2583227.Peer-Reviewed Original ResearchConceptsSmall molecule therapiesSevere plaque psoriasisLaboratory monitoringPlaque psoriasisComorbid conditionsLaboratory monitoring guidelinesIndividual patient's clinical characteristicsPatient clinical characteristicsClinical characteristicsLaboratory valuesPrimary care physiciansPsoriatic arthritisLiver diseasePsoriasisPatientsTherapyCardiovascular diseaseClinical practiceMood disordersMonitoring guidelinesCare physiciansTherapeutic classesComorbiditiesExpert recommendationsDermatologists